Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 4

Awareness of Abdominal Adiposity as a Cardiometabolic Risk Factor (The 5A Study): Mexico

Authors Cuevas Ramos D, Roopa Mehta R, De La Luz Castro J, Limones RC, Ernesto RG, Aguilar Salinas CA

Published 28 March 2011 Volume 2011:4 Pages 107—117

DOI https://doi.org/10.2147/DMSO.S16592

Review by Single-blind

Peer reviewer comments 2


Daniel Cuevas Ramos1, Roopa Mehta1, Julieta De La Luz Castro2, Rutila Castañeda Limones3, Ernesto García Rubí4, Carlos A Aguilar-Salinas1
1Department of Endocrinology, Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran" (INCMNSZ); 2Cardiodiabetes Unit, Sanofi-Aventis de México; 3Clinical Epidemiology Research Unit, Hospital General Regional No 1 Dr Carlos Mac Gregor Sánchez Navarro; 4Department of Endocrinology, Hospital Angeles Metropolitano, Mexico City, Mexico

Background: The Awareness of Abdominal Adiposity as a Cardiometabolic Risk Factor Study assesses the prevalence of cardiometabolic risk factors in adults with abdominal obesity (waist circumference ≥90 cm in men and ≥80 cm in women) and evaluates how physicians manage these patients.
Methods: This is an observational cross-sectional study. Internists, cardiologists, and endocrinologists contributed patients to the study. A standardized questionnaire was completed and registered demographics, anthropometric measurements, lab results from the medical files, and any treatment utilized to manage dyslipidemia, arterial hypertension, diabetes, and cardiovascular disease.
Results: A total of 1312 patients was included. The mean age was 49.3 ± 14.6 years and 834 (63.6%) were female. The primary reason for the physician consultation was treatment of obesity (47.5%), followed by management of arterial hypertension (27.7%), diabetes (18.3%), dyslipidemia (14.2%), and cardiovascular disease (7.1%). The majority of patients identified excess body weight as a health problem (81.4%). However, patients had lost a mean of 4.3 ± 3.5 kg. Only 63.4% of patients with arterial hypertension were on drug therapy. Few of them had reached target values for diastolic (24.1%) and systolic/diastolic (13.3%) pressure. Less than half of the patients with dyslipidemia were receiving lipid-lowering medication. Only 32.2% were at their target low-density lipoprotein cholesterol levels. In patients with type 2 diabetes, mean fasting plasma glucose level (8.9 ± 3.4 mmol/L) was above the threshold recommended by current guidelines.
Conclusions: The study describes the medical care given to individuals with abdominal obesity during daily clinical practice by general practitioners, cardiologists, and endocrinologists in urban Mexico. Our data confirm that a large proportion of patients are undertreated. Only a small percentage of patients with obesity-related comorbidities reach treatment targets. Interventions proven to be effective in the prevention of chronic complications have in general not been implemented.

Keywords: abdominal obesity, waist circumference, dyslipidemia, type 2 diabetes, pattern of care
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]